Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
Categorie
2023
MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents Lyon, France, May 26,…
May 26, 2023
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023 As of March 31, 2023, cash and cash…
May 9, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
May 3, 2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute…
April 24, 2023
[image_with_animation image_url=”9935″ animation=”Grow In” hover_animation=”none” alignment=”center” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”50%” max_width_mobile=”default” img_link=”https://www.ebmt.org/annual-meeting-2023″] MaaT Pharma to Present Clinical Data for MaaT013…
April 11, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
April 4, 2023
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview As of December 31, 2022, cash and cash equivalents…
March 30, 2023
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe MaaT Pharma received…
March 27, 2023
Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General…
March 2, 2023
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.